Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J-P, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.

Article  PubMed  Google Scholar 

Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–76. https://doi.org/10.1016/S0140-6736(20)32439-9.

Article  CAS  PubMed  Google Scholar 

Chang RS, Leung WC, Vassallo M, Sykes L, Battersby Wood E, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev. 2022;2(2): CD005398. https://doi.org/10.1002/14651858.

Article  CAS  PubMed  Google Scholar 

Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35(7):1769–75. https://doi.org/10.1161/01.STR.0000130989.17100.96. (Epub 2004 May 27).

Article  PubMed  Google Scholar 

DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, Garnett L, Fortner CA, Ko D. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–35.

Article  CAS  PubMed  Google Scholar 

Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. 2002;59(9 Suppl 5):S21–6. https://doi.org/10.1212/wnl.59.9_suppl_5.s21.

Article  PubMed  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.

Article  CAS  PubMed  Google Scholar 

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.

Article  CAS  PubMed  Google Scholar 

Jan Steffel and others. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612–76. https://doi.org/10.1093/europace/euab065.

Article  Google Scholar 

Larsson D, Baftiu A, Johannessen Landmark C, von Euler M, Kumlien E, Åsberg S, Zelano J. Association between antiseizure drug monotherapy and mortality for patients with poststroke epilepsy. JAMA Neurol. 2022;79(2):169–75. https://doi.org/10.1001/jamaneurol.2021.4584.

Article  PubMed  Google Scholar 

Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and levetiracetam. Ann Intern Med. 2020;173(9):772. https://doi.org/10.7326/L20-1066.

Article  PubMed  Google Scholar 

Giustozzi M, Mazzetti M, Paciaroni M, et al. Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation. Clin Drug Investig. 2021;41:43–51. https://doi.org/10.1007/s40261-020-00982-8.

Article  CAS  PubMed  Google Scholar 

Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526–36. https://doi.org/10.1002/cpt.2369.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FAERS database. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed Feb. 2023.

Center for Drug Evaluation and Research. National Drug Code Directory. U.S. Food and Drug Administration. 2022. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory. Accessed Feb. 2023.

van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. https://doi.org/10.1002/pds.668.

Article  CAS  PubMed  Google Scholar 

Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug–drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;8(10):1319. https://doi.org/10.3389/fphar.2019.01319.

Article  Google Scholar 

Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug–drug interaction surveillance. Stat Med. 2008;27(16):3057–70. https://doi.org/10.1002/sim.3247. (Erratum in: Stat Med. 2008 Dec 20;27(29):6271-2).

Article  PubMed  Google Scholar 

Apixaban Physician Guidance. https://www.medicines.org.uk/emc/product/2878/smpc#gref. Accessed Feb. 2023.

Apixaban Physician Guidance. FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c#Section_5.3. Accessed, Feb. 2023.

Bolek T, Samoš M, Škorňová I, et al. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study. J Thromb Thrombolysis. 2019;47:140–5. https://doi.org/10.1007/s11239-018-1748-5.

Article  CAS  PubMed  Google Scholar 

Kaba RA, Ara F, Ward DE, Emanuel S. The dabigatran debate. Glob Cardiol Sci Pract. 2014;2014(3):254–6. https://doi.org/10.5339/gcsp.2014.41.

Article  PubMed  PubMed Central  Google Scholar 

Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer DE, Muszkat M. Ischemic and thrombotic events associated with concomitant xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS). CNS Drugs. 2019;33(12):1223–8. https://doi.org/10.1007/s40263-019-00677-5.

Article  CAS  PubMed  Google Scholar 

Rivaroxaban Physician Guidance: https://www.medicines.org.uk/emc/product/2793/smpc#gref. Accessed, Aug. 2023.

Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021;21:208.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menichelli D, Pastori D, Pignatelli P, Pani A. Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. Eur Heart J Case Rep. 2023;7(1): ytad006. https://doi.org/10.1093/ehjcr/ytad006.

Article  PubMed  PubMed Central  Google Scholar 

Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13(1):9257. https://doi.org/10.1038/s41598-023-33876-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mendoza Aguilera M, Bellés Medall MD, Álvarez Martín T, Pascual Marmaneu Ó, LiñanaGranell C, Ferrando PR. Therapeutic drug monitoring of levetiracetam in daily clinical practice: high-performance liquid chromatography versus immunoassay. Eur J Hosp Pharm. 2020;27(e1):e2–6. https://doi.org/10.1136/ejhpharm-2018-001616.

Article  PubMed  Google Scholar 

Ip BY, Ko H, Wong GL, Yip TC, Lau LH, Lau AY, Leng X, Leung H, Chan HH, Chan HY, Mok VC, Soo YO, Leung TW. Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36(12):1313–24. https://doi.org/10.1007/s40263-022-00971-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mathy FX, Dohin E, Bonfitto F, Pelgrims B. Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants. Eur Heart J. 2019;40(19):1571. https://doi.org/10.1093/eurheartj/ehy780.

Article  CAS  PubMed  Google Scholar 

Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46(2):93–9. https://doi.org/10.1016/s0920-1211(01)00253-4.

Article  CAS  PubMed  Google Scholar 

Teng CM, Yeh HI, Lee LG. Anticoagulant and antiplatelet properties of piracetam. Taiwan Yi Xue Hui Za Zhi. 1983;82(11):1104–14.

CAS  PubMed  Google Scholar 

Wang CL, Wu VC, Chang KH, Tu HT, Kuo CF, Huang YT, Chu PH, Kuo CC, Chang SH. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):147–54. https://doi.org/10.1093/ehjcvp/pvz035.

Article  PubMed  Google Scholar 

French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–58. https://doi.org/10.1177/2042098611411127.

Article  PubMed  PubMed Central  Google Scholar 

Sarode R. Direct oral anticoagulant monitoring: what laboratory tests are available to guide us? Hematol Am Soc Hematol Educ Program. 2019;2019(1):194–7. https://doi.org/10.1182/hematology.2019000027.

Article  Google Scholar 

Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment. CNS Drugs. 2023;37(3):203–14. https://doi.org/10.1007/s40263-023-00990-0.

Article  CAS  PubMed  Google Scholar